At Protheragen, we help out-license and find co-development opportunities for drug development programs. We aspire to play a role in transforming the scientific innovations into medications, helping patients with the most challenging diseases. Our main focus is on oncology programs. Most programs that are available on the list below are at preclinical stage with great therapeutic and market potential.
If you are interested in any of the projects, please contact us for further discussion. We look forward to our collaboration.
| Program | Indication | Target | Discovery | Preclinical | PhaseⅠ | PhaseⅡ | PhaseⅢ |
| Antibody Therapy | |||||||
| Antibody Product Portfolio | Cancer | Multiple targets |
|
||||
| ANTIGN-109 | Cancer | GnRHR |
|
||||
| ANTICA-201 | Cancer | CA215 |
|
||||
| CD3XCD20 bsAb | Lymphomas | CD3; CD20 |
|
||||
| Anti-MUC1-Ab | Solid tumor | MUC1 |
|
||||
| CD3xBCMA-bsAb | Multiple myeloma | CD3; BCMA |
|
||||
| Anti-CD40-7409 | Cancer | CD40 |
|
||||
| BioLink018 | Non-Hodgkin lymphoma | CD79B |
|
||||
| Anti-CD137-6051 | Cancer | CD137 |
|
||||
| IGY-110 | Covid-19 | Spike proteins |
|
||||
| Anti-LAG3 mAb | Cancer | LAG3 |
|
||||
| OX40-Ab | Cancer | OX40 |
|
||||
| A1801 ADC | Breast cancer; Melanoma | GPNMB |
|
||||
| PMB-104 | Asthma | Immunoglobulin E |
|
||||
| PMB-107 | Solid tumor | GARP/LAP-TGFβ1 complex |
|
||||
| PBI-108 | Solid tumor | PD-1 and Siglec-15 |
|
||||
| PMB-109 | Asthma | TSLP |
|
||||
| PMB-131 | IgA nephropathy | MASP-2 |
|
||||
| PBI-203 | Solid tumor | PD-L1 and VEGF |
|
||||
| PBI-204 | Sepsis | Adrenomedullin |
|
||||
| PBI-205 | Solid tumor | PD-1 and PD-L1 |
|
||||
| PMB-211 | Fibrosis | CTGF |
|
||||
| Recombinant Protein Therapy | |||||||
| APD-IL10 | Solid tumor | IL-10; PD-1 |
|
||||
| P75NEURO | Neurological diseases | p75NTR (NGFR) |
|
||||
| P11 | Type 2 diabetes | GLP-1 receptor |
|
||||
| Angiocidin | Acute myeloid leukemia | Death receptor 6 |
|
||||
| TT-173 | Surgical bleeding and trauma |
|
|||||
| ROD-16 | Hyperoxaluria |
|
|||||
| BioLink001 | Solid tumor | IL-15 |
|
||||
| JZ-603 | Allergic asthma; Allergic rhinitis | IgE |
|
||||
| PepTRx anti-HIV | AIDS | HIV proteins |
|
||||
| Oncolytic Virotherapy | |||||||
| RV-scFv-PDL1 | Cancer | PD-L1 |
|
||||
| OV-FV-01 | Cancer | Confidential |
|
||||
| BS001 | Cancer |
|
|||||
| Small Molecules | |||||||
| IVW-1001 | Dry eye disease | TRPM8 |
|
||||
| Polyoxygenated Cyclohexene Compound 4 | Pain | Nav1.7 |
|
||||
| PPM-100 | Cancer | IKZF1/3 |
|
||||
| Fascin Inhibitor | Cancer | Fascin |
|
||||
| Resveratrol (Micellar) | Alzheimer’s disease | SIRT1 |
|
||||
| NMMHC IIA Inhibitors | Thrombosis | NMMHC IIA |
|
||||
| VISTA Agonist | Psoriasis | VISTA |
|
||||
| Berbamine Analogues | (+)ssRNA virus infections | TRPML |
|
||||
| Intravenous Anesthetics | Anesthesia | GABA(A) receptor |
|
||||
| Water-soluble Taxanes | Cancer | Tubulin |
|
||||
| CQ-527 | Cancer | Tubulin |
|
||||
| FHND41 | NSCLC | EGFR |
|
||||
| BioLink1006 | Metastatic cancer | EGFR |
|
||||
| BioLink2018 | B-cell lymphomas | BTK |
|
||||
| BioLink2020 | Solid tumor | FGFR1-3 |
|
||||
| BioLink2022 | Heart failure | PDE9 |
|
||||
| BioLink2024 | Inflammatory diseases | NLRP3 |
|
||||
| FHND91 | Multiple myeloma | Proteasome |
|
||||
| FHND71 | Solid tumor | RET |
|
||||
| Cell Therapy | |||||||
| Double Negative T Cells | Acute myelocytic leukemia | Multi-target |
|
||||
| Anti-BCMA CAR-T Cell | Multiple myeloma | BCMA |
|
||||
| Anti-GPRC5D CAR T-cell | Multiple myeloma | GPRC5D |
|
||||
| GCC-CART | Metastatic colorectal cancer | GUCY2C |
|
||||
| Gene Therapy | |||||||
| RNA4TNBC | Triple-negative breast cancer | MIR34A; MIR21 |
|
||||
| Others | |||||||
| IVIEW-1201 | Conjunctivitis |
|
|||||
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |